Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease

Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease

Sickle cell disease (SCD) is a pathophysiological condition of chronic hemolysis, oxidative stress, and elevated inflammation. The transcription factor Nrf2 is a master regulator of oxidative stress. Here, we report that the FDA-approved oral agent simvastatin, an inhibitor of hydroxymethyl-glutaryl...

Full description

Bibliographic Details
Main Authors: Caixia Xi, Chithra Palani, Mayuko Takezaki, Huidong Shi, Anatolij Horuzsko, Betty S. Pace, Xingguo Zhu
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Antioxidants
Subjects:
sickle cell disease
simvastatin
Nrf2
enhancer of zeste homolog 2
histone methylation
fetal hemoglobin
Online Access:https://www.mdpi.com/2076-3921/13/3/337

Similar Items

Similar Items